Print Page  Close Window

Press Releases
Keyword Search
2017 | 2016 | 2015 | 2014
06.08.17Zynerba Pharmaceuticals Achieves Target Enrollment in Exploratory Phase 2 Trial of ZYN002 in Fragile X SyndromePrinter Friendly Version
06.01.17Zynerba Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare ConferencePrinter Friendly Version
05.09.17Zynerba Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational HighlightsPrinter Friendly Version
03.27.17Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Operational HighlightsPrinter Friendly Version
03.13.17Zynerba Pharmaceuticals to Report Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 27, 2017Printer Friendly Version
03.13.17Zynerba Pharmaceuticals Announces Completion of Enrollment for ZYN002 in Two Phase 2 Clinical Trials for Epilepsy and OsteoarthritisPrinter Friendly Version
03.01.17Zynerba Pharmaceuticals to Participate in Upcoming Investor ConferencesPrinter Friendly Version
02.09.17Zynerba Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional SharesPrinter Friendly Version
01.19.17Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common StockPrinter Friendly Version
01.18.17Zynerba Pharmaceuticals Announces Proposed Public Offering of Common StockPrinter Friendly Version
01.03.17Zynerba Pharmaceuticals Announces Initiation of the FAB-C Exploratory Phase 2 Clinical Trial of ZYN002 CBD Gel in Patients with Fragile X SyndromePrinter Friendly Version